bullish
Actinogen Releases Phase II Interim Result and Receives US Cornerstone Investment
105 Views23 May 2018 12:35
Actinogen Medical Ltd (ACW AU) announced the results of the Interim Analysis of its Phase II XanADu trial that is conducted independently by the...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Winnie Wong
Healthcare Specialist
Price Chart(Sign Up to Access)
- Actinogen Releases Phase II Interim Result and Receives US Cornerstone Investment23 May 2018
- New FDA Draft Rules Ease Approval for Alzheimer's Drugs28 Mar 2018
- Will Actinogen Ace Alzheimer's?01 Mar 2018
x